Pantogerolan (Pantoprazole)

Pantoprazole, the active ingredient in Pantogerolan, is a proton pump inhibitor presented as an oral dosage form for oral use. It reduces gastric acid production and is indicated for conditions such as gastro‑oesophageal reflux disease, erosive esophagitis, and peptic ulcer disease in adult patients.

GNH USA supplies Pantogerolan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality and regulatory compliance across markets.

Pantoprazole is a proton pump inhibitor used to manage acid‑related gastrointestinal disorders. - Gastro‑oesophageal reflux disease (GERD): provides symptomatic relief by decreasing gastric acid exposure to the esophagus. - Erosive esophagitis: promotes healing of damaged esophageal mucosa through acid suppression. - Peptic ulcer disease: facilitates ulcer healing and prevents recurrence by maintaining a low‑acid gastric environment.

Pantoprazole may be associated with a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhea: loose stools often transient. - Nausea: occasional feeling of queasiness. - Abdominal pain: mild discomfort in the stomach area.

Serious or Rare Side Effects: - Acute interstitial nephritis: inflammation of kidney interstitium. - Severe allergic reactions: rash, angioedema, or anaphylaxis. - Clostridioides difficile infection: severe colitis risk. - Osteoporotic fractures: increased risk with long‑term use.

When prescribing Pantogerolan, clinicians should consider several precautionary measures to ensure safe use. - Assess renal function: dose adjustment may be needed in severe impairment. - Monitor for hypomagnesemia: prolonged therapy can lower serum magnesium. - Evaluate for osteoporosis risk: long‑term use may affect bone density. - Use with caution in hepatic impairment: limited data in severe liver disease. - Avoid abrupt discontinuation: may cause rebound acid hypersecretion. - Store at room temperature: keep below 25 °C, retain in original packaging, protect from moisture.

Pantogerolan can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet effect due to CYP2C19 inhibition. - Atazanavir or other protease inhibitors: decreased absorption leading to subtherapeutic levels. - Methotrexate: increased serum concentrations and toxicity risk. - Warfarin: potential enhancement of anticoagulant effect.

Moderate Interactions (Monitor Closely): - Digoxin: increased serum levels, monitor for toxicity. - Phenytoin: reduced plasma concentration, adjust dose if needed. - Iron supplements: decreased absorption of pantoprazole, separate administration times.